FIDSON
Investo's verdict, shared with you
Fidson Healthcare Plc is a quality Nigerian pharma compounder with demonstrable earnings momentum — H1 2026 revenue of ₦74.5bn (+17.2% YoY) and PAT of ₦7.7bn — underpinned by a 16.7% ROE and a clean, ungeared balance sheet (equity of ₦59.1bn against total assets of ₦110.4bn). However, at the current price of ₦83.5 (implied P/E of ~20.3x on ₦4.12 EPS), the stock trades materially above our blended fair value of ₦68.63, leaving no margin of safety despite the genuine operational quality. The honest read is that this is a good business priced for perfection, and further upside requires either a meaningful earnings re-rating or continued multiple expansion that the historical record does not yet justify.
Verdict published 2026-10-26 · fundamentals through Q2-2026 · reviewed as the data changes
Verdict moderated to Hold — Avoid was refused
Committee scores Value POSITIVE (overall strong); an "avoid" against our own committee is not publishable without a re-derivation.
Source: NGX live market data · Investo intelligence. Educational only — not financial advice.